BioNTech tests new cancer drug in first human trial
NCT ID NCT07455734
Summary
This is the first time the experimental drug BNT3214 will be given to people. The study aims to find safe doses and see if it helps adults with advanced solid tumors that have stopped responding to standard treatments. Researchers will test different dose levels in small groups first, then expand to more participants with specific cancer types to check for early signs of effectiveness.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Epworth HealthCare
NOT_YET_RECRUITINGRichmond, 3121, Australia
-
Monash Medical Centre Clayton
NOT_YET_RECRUITINGFitzroy, 3065, Australia
-
National Taiwan University Hospital
NOT_YET_RECRUITINGTaipei, 100225, Taiwan
-
Shanghai East Hospital
RECRUITINGShanghai, 200120, China
Conditions
Explore the condition pages connected to this study.